Sofia Birkeälv

Sofia Birkeälv's work experience is as follows:

Sofia currently works at SAGA Diagnostics AB as a Senior Scientist & NGS Lead, starting in January 2023. Previously, they held the role of Molecular Diagnostics Scientist and NGS Lead at the same company from March 2020 to February 2023.

Prior to that, Sofia was a PhD Student at the Wellcome Sanger Institute, University of Cambridge from January 2016 to March 2020. Sofia'sresearch focused on melanoma genetics and immuno-oncology, where they profiled the genetic landscape of melanoma tumors and conducted CRISPR-Cas9 screening to study tumor PD-L1 expression.

Sofia also participated in the Innovative Medicines Graduate Programme at AstraZeneca from November 2013 to November 2015.

Before their graduate studies, they worked at BioInvent International AB as a Master Thesis student from January 2013 to June 2013. Sofia'sthesis involved generating antibodies against murine pancreatic cancer cells using a novel drug discovery approach. Sofia also completed a project course at BioInvent International AB in November to December 2012.

Additionally, Sofia worked as a Laboratory Assistant at Alcontrol Laboratories from January 2012 to January 2013, performing microbiological analysis of food and water pathogens part-time while studying.

Sofia Birkeälv completed their education with a Doctor of Philosophy (PhD) degree in Biology/Biological Sciences, General from the University of Cambridge from 2016 to 2020. Prior to that, they attended The Faculty of Engineering at Lund University from 2008 to 2013, where they obtained their degree in 2013, although the field of study is not specified. Additionally, in 2011, they studied Biotechnology at the University of Connecticut for a brief period.